RGX-314 provided 2-Step or more improvement in diabetic severity in Phase 2 Altitude study analysis
September 2nd 2022The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.
Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients
September 1st 2022Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.
EURETINA celebrates women in retina
August 28th 2022The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.
Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidate
August 13th 2022The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Intravenous bevacizumab repackaged for intravitreal use: Making the sight-saving treatment safer
August 10th 2022Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
The need for precision management in glaucoma moves field forward
August 8th 2022Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
High-tech, noninvasive imaging identifies early glaucoma
August 6th 2022Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.